MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Neoleukin Therapeutics EPS Ratio 2011-2025 | NLTX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.8 | -1.04 | -1.1 | -0.64 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -49.5 | -40.2 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.8 | -49.5 | -6.44 |
Quarterly EPS Ratio Neoleukin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.99 | -1.05 | -1.08 | - | -1.19 | -1.09 | -1 | - | -32.7 | -26.7 | -0.26 | - | -1.18 | -0.28 | -0.28 | - | -0.28 | -0.27 | -0.27 | - | -0.04 | -0.2 | -0.18 | - | -2.26 | -0.09 | -0.09 | - | -0.64 | 0.12 | -0.62 | - | -0.5 | -0.59 | -0.36 | - | -0.46 | -0.63 | -0.39 | - | -0.43 | -0.44 | -0.6 | - | -0.59 | -0.51 | -1.28 | - | -15.6 | -7.89 | -8.48 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.12 | -32.7 | -2.86 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
-4.67 | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.69 | -3.13 % | $ 182 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-0.5 | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
-4.1 | $ 5.18 | -4.17 % | $ 86.3 M | Canada |
 |
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
-14.8 | $ 11.76 | 2.98 % | $ 602 M | USA |
 |
Evoke Pharma
EVOK
|
-2.33 | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | $ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
-0.81 | $ 7.17 | 1.85 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
-0.75 | $ 46.47 | -1.25 % | $ 1.52 B | USA |
 |
China Pharma Holdings
CPHI
|
-0.27 | $ 1.55 | -0.64 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
-1.62 | $ 6.83 | -1.37 % | $ 2.49 B | Canada |
 |
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
-0.01 | $ 4.86 | 0.73 % | $ 640 M | USA |
 |
OrganiGram Holdings
OGI
|
-0.51 | $ 1.82 | -5.36 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 3.03 | 19.57 % | $ 42.6 M | USA |
 |
Pacira BioSciences
PCRX
|
-2.15 | $ 26.71 | 1.6 % | $ 1.24 B | USA |
 |
Rockwell Medical
RMTI
|
-0.37 | $ 0.88 | -5.09 % | $ 20.5 M | USA |
 |
Solid Biosciences
SLDB
|
-3.06 | $ 5.81 | -1.02 % | $ 237 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 3.45 | -3.96 % | $ 4.28 M | USA |
 |
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-3.28 | $ 4.32 | 6.4 % | $ 130 M | USA |
 |
Jupiter Wellness
JUPW
|
-0.91 | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
-1.25 | $ 12.85 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
1.17 | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | USA |
 |
Sundial Growers
SNDL
|
-1.1 | $ 2.02 | -8.68 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
-0.28 | $ 2.43 | 0.41 % | $ 328 M | USA |
 |
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-1.79 | $ 1.4 | 14.75 % | $ 6.04 M | USA |
 |
SCYNEXIS
SCYX
|
1.4 | $ 0.64 | -1.21 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
-2.35 | $ 11.41 | -6.09 % | $ 7.05 B | Canada |
 |
TherapeuticsMD
TXMD
|
-0.98 | $ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
-0.035 | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
1.71 | $ 11.68 | 0.21 % | $ 14.2 B | USA |